Therapy Response Imaging in Oncology

Part I Imaging as a "Common Language" for Treatment Response Evaluations in Oncology.- Conventional Tumor Response Criteria and Limitations.- Response Evaluations for Precision Cancer Therapy and Immunotherapy.- Part II Practical Pitfalls in Therapy Response Imaging in Cancer Patients.- Drug Toxicity, Approach to Cancer as a Systemic Disease, and imaging modality-specific considerations.- Part III Disease-specific Approach for Therapy Response Imaging.- Therapy Response Imaging in Central Nervous System (CNS) Malignancy.- Therapy Response Imaging in Breast Cancer.- Therapy Response Imaging in Thoracic Malignancy.- Therapy Response Imaging in Gastrointestinal Malignancy.- Therapy Response Imaging in Hepatobiliary and pancreatic malignancies.- Therapy Response Imaging in Genitourinary Malignancies.- Therapy Response Imaging in Gynecologic malignancies.- Therapy Response Imaging in Lymphoma and Hematologic Malignancies.- Therapy Response Imaging in Sarcoma and musculoskeletal malignancies.- Part IV: Emerging Approaches and Future Directions.- Radiomics and Imaging Genomics for Evaluation of Tumor Response.- Evolution of Clinical Trial Imaging and Co-clinical Imaging.- Molecular and Functional Imaging in Oncology Therapy Response.

Mizuki Nishino is a diagnostic radiologist specialized in oncologic imaging, with a particular focus on therapy response imaging in the setting of precision cancer therapy and cancer immunotherapy. Dr. Nishino is a fellowship-trained thoracic radiologist. Her research has focused on therapy response imaging in lung cancer treated with molecular targeting therapy, contributing to the identification of objective imaging markers to predict treatment benefit and clinical outcome. Dr. Nishino has also applied her expertise to therapy response imaging in cancer immunotherapy and has published a series of fundamental studies to refine strategies for immune-related response evaluation. In addition she has made contributions to imaging-based characterization of drug toxicities in cancer patients treated with precision therapy and immunotherapy. Dr. Nishino published the first report of clinical and imaging characteristics of immune checkpoint inhibitor-related pneumonitis, defined the spectrumof radiographic manifestations of the entity, and continues to work on the topic to develop strategies for early detection and accurate diagnosis.